[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-331568-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-331568-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","the-role-of-mir-152-in-urological-tumors-potential-biomarkers-and-therapeutic-targets","The role of miR-152 in urological tumors: potential biomarkers and therapeutic targets","","Urological malignant tumors threaten health, with high global incidence and mortality and persistently unfavorable prognosis driven by late detection, postoperative recurrence, and therapy resistance. MicroRNAs, small non-coding regulators of gene expression via 3’ UTR binding, influence proliferation, differentiation, apoptosis, and migration. Dysregulated miRNAs can alter oncogene and tumor suppressor pathways. This review consolidates evidence on miR-152 expression and function in prostate cancer, bladder cancer, and renal cell carcinoma, clarifying mechanisms and evaluating miR-152 as a biomarker and therapeutic target in urological malignancies.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/the-role-of-mir-152-in-urological-tumors-potential-biomarkers-and-therapeutic-targets/331568/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/the-role-of-mir-152-in-urological-tumors-potential-biomarkers-and-therapeutic-targets/331568.png","ImageObject",300,407,{"name":42,"@type":43},"Evangeline","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why are urological malignancies difficult to manage clinically?","Question",{"text":63,"@type":64},"Early stages often lack specific symptoms, leading to advanced-stage diagnosis. Current biomarkers and diagnostic approaches have limitations, and advanced cases face treatment resistance after chemotherapy or radiotherapy.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What biological role do microRNAs play in cancer?",{"text":68,"@type":64},"MicroRNAs are small non-coding RNAs that regulate gene expression by binding to the 3’ untranslated region of target mRNAs. Dysregulation can disturb oncogene and tumor suppressor gene expression, affecting key cancer processes.",{"name":70,"@type":61,"acceptedAnswer":71},"What does this review focus on regarding miR-152?",{"text":72,"@type":64},"It reviews miR-152 expression and function in prostate cancer, bladder cancer, and renal cell carcinoma, describing mechanisms in cancer progression and assessing its potential as a therapeutic target and biomarker.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},331568,1790007260,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":112,"preview_page_count":4},13056703019662,"https://ap-avatar.wpscdn.com/avatar/be000253a8e92610077?_k=1778726343310543188","TYPE Review  \nPUBLISHED 13 November 2024 DOI 10.3389/fimmu.2024.1464327  \nOPEN ACCESS  \nEDITED BY  \nGiandomenico Roviello, University of Firenze, Italy  \nREVIEWED BY  \nSoumasree De,  \nUniversity of Bern, Switzerland Ying Shi,  \nHuazhong University of Science and Technology, China  \n*CORRESPONDENCE  \nXinsheng Zhang  \n [zhangxs0624@163.com](zhangxs0624@163.com)[ ](zhangxs0624@163.com)Jian He  \n[jianhe20200606@163.com](jianhe20200606@163.com)  \n†These authors have contributed equally to this work  \nRECEIVED 13 July 2024  \nACCEPTED 28 October 2024  \nPUBLISHED 13 November 2024  \nCITATION  \nLi X, Qian B, Chen X, Shen M, Zhao S, Zhang X and He J (2024) The role of miR-152 in urological tumors: potential biomarkers and therapeutic targets.  \nFront. Immunol. 15:1464327 .  \ndoi: 10.3389/fimmu.2024.1464327  \nCOPYRIGHT  \n© 2024 Li, Qian, Chen, Shen, Zhao, Zhang and He. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nThe role of miR-152 in urological tumors: potential biomarkers and therapeutic targets  \nXin Li 1†, Biao Qian 2†, Xu Chen 3†, Maolei Shen 1, Shankun Zhao 1, Xinsheng Zhang 1* and Jian He 1*  \n1 Department of Urology, Taizhou Central Hospital (Taizhou University Hospital), Taizhou, Zhejiang, China, 2 Department of Urology, First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi, China, 3 Department of Pathology, The Third Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China  \nUrological malignant tumors pose a significant threat to human health, with a high incidence rate each year. Prostate cancer, bladder cancer, and renal cell carcinoma are among the most prevalent and extensively researched urological malignancies. Despite advancements in research, the prognosis for these tumors remains unfavorable due to late detection, postoperative recurrence, and treatment resistance. A thorough investigation into their pathogenesis is crucial for early diagnosis and treatment. Recent studies have highlighted the close association between microRNAs (miRNAs) and cancer progression. miRNAs are small non-coding RNAs composed of 19-23 nucleotides that regulate gene expression by binding to the 3’ untranslated region (3 ’ UTR) of target mRNAs, impacting key cellular processes such as proliferation, differentiation, apoptosis, and migration. Dysregulation of miRNAs can disrupt the expression of oncogenes and tumor suppressor genes, contributing to cancer development. Among the various miRNAs studied, miR-152 has garnered attention for its role inurological malignancies. Several studies have indicated that dysregulation of miR-152 expression is significant in these cancers, warranting a comprehensive review of the evidence. This review focuses on the expression and function of miR-152 in prostate cancer, bladder cancer, and renal cell carcinoma, elucidating its mechanisms in cancer progression and exploring its potential as a therapeutic target and biomarker in urological malignancies.  \nKEYWORDS  \nmiR-152, urological malignancy, therapeutic target, biomarker, microRNA  \nIntroduction  \nUrological malignancies encompass prostate cancer, bladder cancer, renal cell carcinoma, penile cancer, testicular cancer, and uroepithelial cancer. According to GLOBOCAN, there were approximately 2.5 million new cases of urological malignancies globally in 2022, representing 12.6% of all cancers. These cases resulted in 770,000 deaths, accounting for  \nFrontiers in Immunology 01 [frontiersin.org](frontiersin.org)  \n8% of all cancer-related deaths (1). The number of new cases and deaths of urinary malignant tumors in 2022 has exceeded th","cbCaim56RMJNlgV9","https://ap.wps.com/l/cbCaim56RMJNlgV9","pdf",2310112,12,"English","# Introduction\n## Background and epidemiology of urological malignancies\n## Diagnostic and treatment challenges\n# microRNAs and cancer progression\n# Focus of the review on miR-152","[{\"question\":\"Why are urological malignancies difficult to manage clinically?\",\"answer\":\"Early stages often lack specific symptoms, leading to advanced-stage diagnosis. Current biomarkers and diagnostic approaches have limitations, and advanced cases face treatment resistance after chemotherapy or radiotherapy.\"},{\"question\":\"What biological role do microRNAs play in cancer?\",\"answer\":\"MicroRNAs are small non-coding RNAs that regulate gene expression by binding to the 3’ untranslated region of target mRNAs. Dysregulation can disturb oncogene and tumor suppressor gene expression, affecting key cancer processes.\"},{\"question\":\"What does this review focus on regarding miR-152?\",\"answer\":\"It reviews miR-152 expression and function in prostate cancer, bladder cancer, and renal cell carcinoma, describing mechanisms in cancer progression and assessing its potential as a therapeutic target and biomarker.\"}]","The role of miR-152 in urological tumors: potential biomarkers and therapeutic targets | PDF",1789994027]